Intra Cellular Therapies | ITCI - Чистый доход



Чистый доход Изменить Дата
Acadia Pharmaceuticals USD 273.57M 201.79M 2025-12
ALKERMES USD 49.34M 33.42M 2025-12
BioCryst Pharmaceuticals USD 245.84M 232.95M 2025-12
Biogen USD 466.5M 168.3M 2025-09
Bristol-Myers Squibb USD 1.09B 1.11B 2025-12
Cytokinetics USD -183.03M 123.15M 2025-12
Esperion Therapeutics USD 61.83M 93.16M 2025-12
Gilead Sciences USD 2.18B 869M 2025-12
Halozyme Therapeutics USD -141.59M 316.82M 2025-12
J&J USD 5.12B 36M 2025-12
Minerva Neurosciences USD 1.44M 21.07M 2024-12
Nektar Therapeutics USD -37.06M 15.31M 2024-09
Neurocrine Biosciences USD 209.5M 102M 2025-09
Novartis USD 2.41B 1.52B 2025-12
Prothena USD -21.59M 14.95M 2025-12
RedHill Biopharma USD -1.54M 0 2024-06
Supernus Pharmaceuticals USD -45.12M 67.62M 2025-09
United Therapeutics USD 364.3M 25.6M 2025-12
Vanda Pharmaceuticals USD -18.9M 13.58M 2024-12